Benign Prostatic Hyperplasia News

Below are three under the radar stocks from the healthcare sector that I have been following for the past 3-6 months which have upcoming catalysts in the form of expected strategic deals, clinical trial results, and other corporate developments.

HASBROUCK HEIGHTS, NJ Nymox Pharmaceutical Corporation announced today the release of positive new clinical trial data from responder analysis of the Company's pooled multicenter U.S. Phase 2 studies of NX-1207, indicating durable early responder benefits from Nymox's innovative drug treatment for benign prostatic hyperplasia .

Unapproved non-steroidal and tissue-selective anabolic drugs called selective androgen receptor modulators are being sold on the Internet as sports doping agents, according to a new report.

The availability of authentic SARMs was recently demonstrated for the first time by the detection of the drug candidate Andarine in a product sold via the Internet.

Nearly every man over 45 has some degree of enlargement of the prostate gland, which slowly progresses throughout the aging process.

Can a healthy lifestyle lower risk of benign prostate enlargement? Benign prostatic hyperplasia, known as BPH, is an enlargement of the prostate gland that is not malignant .

Sanofi-Aventis received a warning letter from the FDA's division of drug marketing, advertising, and communications after the company distributed a misleading promotional card for Uroxatral, an alpha1-blocker used to treat urinary problems caused by an enlarged prostate.

Two of the most common prostate problems are the Benign Prostatic Hyperplasia and the prostatitis.

The FDA today posted on its website a letter sent to Sanofi-Aventis regarding a voucher tent card for Uroxatral.

WYRE Foresta s MP is backing a campaign highlighting a prostate problem affecting more than a third of men aged over 50.

ADAM. "Benign Prostatic Hyperplasia In-Depth." 03 April 2007. HowStuffWorks.com. 13 October 2009.

Nymox Pharmaceutical Corporation is pleased to announce that NX-1207, the Company's lead drug in development, has been shown to produce strongly positive and repeatable results in laboratory studies of human prostate cancer.

"For many men BPH is a progressive disease causing discomfort, inconvenience and embarrassment.A CombAT provides evidence that dutasteride and tamsulosin together may benefit these men, potentially reducing the long-term risk of disease progression and improving their symptoms." said Dr Claus G. Roehrborn, principal investigator and lead author of ...

AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia , met its primary endpoint.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Main Category: Urology / Nephrology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 07 Oct 2009 Impax Laboratories, Inc.

HAYWARD,A Calif. A specialty pharmaceutical company announced the tentative approval of its benign prostatic hyperplasia treatment.

DEAR MAYO CLINIC:I was recently diagnosed with BPH. At what point would you recommend treatment? What are my treatment options? ANSWER: Many options exist to treat benign prostatic hyperplasia , including watchful waiting, medications, nonsurgical therapies, and surgery .

Holmium Laser Enucle ation of the Prostate : The Endourologic Alternative to Open Prostatectomy.

The US FDA has granted tentative approval to wockhardt Ltd for marketing its 0.4mg tamsulosin hydrochloride capsules, used for treating benign prostatic hyperplasia .